At a glance

ClinicalIndex Comparison Record

Phase 2Unknown· 64 target

Drug / intervention

Routine dose icotinib +1 moredrug

Likely dose

Routine dose icotinib 125 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02027090

NCT02027090Phase 2Unknown

Compare CT.gov

High Dose Versus Routine Dose Icotinib in Pretreated Non-small Cell Lung Cancer Patients With Stable Disease: a Phase II Randomized Study

Betta Pharmaceuticals Co., Ltd.·interventional·Posted Jan 3, 2014·Updated May 22, 2015

In Brief

A Phase 2 clinical trial evaluating Routine dose icotinib and Higher dose icotinib for Non-small Cell Lung Cancer. Targeting 64 participants across 1 site.

Detailed Summary

We hypothesize that higher dose icotinib is related with better efficacy. The primary objective is to compare the progression-free survival of higher dose and routine dose of icotinib in treating pretreated advanced non-small cell lung cancer patients with stable disease after 8-week routine dose icotinib treatment.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsNon-small Cell Lung Cancer

CountriesChina

Collaborators--

Timeline

Phase 2UnknownOverdue

2014201520162017201820192020202120222023202420252026

Enrollment StartJan 2014

First PostedJan 2014

Primary CompletionJun 2016

Study CompletionDec 2016

TodayJul 2026

First PostedJan 3, 2014

Enrollment StartJan 1, 2014

Primary CompletionJun 1, 2016

Study CompletionDec 1, 2016

TodayJul 1, 2026

Enrollment to primary: 2.4 yearsPosted 12.5 years ago

Interventions

Routine dose icotinibdrug

Icotinib is administered 125 mg three times daily.

Higher dose icotinibdrug

After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day.